Diabetes

A retrospective cohort study found that GLP-1 exposure after breast cancer diagnosis was associated with improved overall survival among patients with type 2 diabetes.

A systematic review found wearable technologies could support diabetic foot ulcer monitoring and early risk detection, while highlighting the need for stronger clinical evidence.

One in four adults with Type 2 diabetes are estimated to experience clinically significant hearing loss.

Diabetes UK and the Department of Health & Social Care have partnered to address cardiovascular disease.

Discontinuation of treatment with GLP-1 receptor agonists has been tied to an increased risk of psychiatric events in people with Type 2 diabetes.

SHR could serve as a readily available biomarker to identify individuals at greater risk of geriatric syndromes

New YouGov data has revealed that public perceptions on weight loss drugs in the UK are split.

GLP-1 receptor agonist therapy has been linked to smell and taste disturbances in patients with Type 2 diabetes.